

Early Conventional Polytherapy Slows RA Course

BY BRUCE K. DIXON
Chicago Bureau

CHICAGO — In the era of biologically active agents for rheumatoid arthritis, it is worth remembering that early treatment with other disease-modifying antirheumatic drugs such as methotrexate, either alone or in combination, also can preserve joint architecture, usually with fewer complications and for significantly less money, Dr. James R. O'Dell said at a symposium sponsored by the American College of Rheumatology.

Evaluation of disease-modifying antirheumatic drug (DMARD) monotherapy shows that early treatment with methotrexate slows disease progression and improves survival, said Dr. O'Dell, who is professor of medicine at the University of Nebraska Medical Center in Omaha. "And the earlier the better; if we treat early, we can put a high percentage of patients in remission," he said, stressing that directing therapy at a specific target may improve outcome, as shown by the TICORA trial (Lancet 2004;364:263-9).

"They did not use biologics in the TICORA trial, but rather they ramped patients up to triple therapy. But the important thing is that they had a target, which was to accomplish a disease activi-

ty score of under 2.4, which equates to one or two tender or swollen joints. What they found was that those who got treatment with that target in mind did better," Dr. O'Dell explained.

If the patient wants to avoid side effects and lab tests, and payment is a problem, hydroxychloroquine is a good drug to consider. "It's the safest DMARD and the only test that's required is an annual eye exam," he said.

Another option is minocycline, a small-molecule medication which, like doxycycline, upregulates interleukin-10 production, and which outperformed hydroxychloroquine in a head-to-head study, the goal of which was to get patients to American College of Rheumatology rating scale (ACR) 50 in 2 years (Arthritis Rheum. 2001;44:2235-41). Caveats include the fact that minocycline's effectiveness in RA has been primarily demonstrated in seropositive patients. And in about 40% of patients treated longer than 2 years, minocycline may cause hyperpigmentation that is slow to resolve after the drug



is discontinued, Dr. O'Dell cautioned.

Another option is azathioprine, which Dr. O'Dell called "a sort of forgotten drug. We use this in combination with methotrexate because it's effective and affordable for people with high copays."

Combinations of DMARDs also preserve joints in RA. Tested combinations include:

▶ Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine.

▶ Sulfasalazine, methotrexate, and high-dose prednisone (COBRA combo).

▶ Methotrexate and the tumor necrosis factor- α (TNF- α) inhibitors.

Combination therapy (methotrexate, sulfasalazine, and hydroxychloroquine)

was pitted against monotherapy (any

one of these drugs) in what Dr. O'Dell called a somewhat obscure Turkish study.

"What they showed was that three drugs are better than two and two drugs are better than one. In the three-drug group, 69% of patients had no radiographic progression, compared with 64% in the two-drug group and 24.5% in the monothera-

py cohort," he said (Clin. Exp. Rheumatol. 1999;6:699-704).

More recently, the PREMIER study of adalimumab and methotrexate alone or in combination showed that combining drugs was the best thing to do (Arthritis Rheum. 2006;54:26-37). "More drugs are better than fewer drugs if what you're striving for is efficacy. When we look at ACR 50, the two drugs alone were similar. However, achievement of ACR 20 statistically favored methotrexate (over the TNF inhibitor) and that's interesting," explained Dr. O'Dell, adding that those taking a combination of the two drugs had the best clinical responses and the least radiographic progression. Of those PREMIER patients on combination therapy, 61% had no radiographic progression. However, the benefits came at a cost: Those receiving the TNF inhibitor had a significant increase in serious infections.

The side effects of TNF inhibitors, underscore the importance of screening patients for tuberculosis and other infections before placing them on these biologics, Dr. O'Dell stressed. "Infections are a concern ... and if we hide our heads in the sand, we're doing our patients a disservice. These are extremely effective drugs, but we just need to take appropriate precautions." ■

CLASSIFIEDS

Also Available at www.familypracticenews.com

CONTINUING EDUCATION

COSMETIC PROCEDURES for MEDICAL OFFICES & MEDSPAS

Small Group Demo & Hands-On Training

- Botox®, Cosmetic Fillers, and Sculptra™
- Sclerotherapy/Laser for Leg Veins
- Lasers/IPL for Hair Removal, Pigment, Acne, Rosacea, Tissue Tightening
- Body Contouring by Mesotherapy and Tumescence Liposuction (NY only)
- Spa Services: Microdermabrasion, chemical peels, and cosmeceuticals

Two-day workshops held monthly:

- June 23-24 Las Vegas
- July 13-14 Vancouver
- August 12-13 New York City
- September 16-17 New York City
- September 21-22 Vancouver
- October 21-22 New York City

For more information, visit www.MDcosmetic-laser.com
or call Ellen Duncan @914-260-8017

Faculty

Neil C. Goodman, M.D., Ph.D., FACOG, Allergan National Faculty Speaker, American Society for Laser Medicine & Surgery, American Academy of Cosmetic Surgery & Liposuction Society

Haneef Alibhai, MDCM, President, Canadian Association of Aesthetic Medicine, Western Canadian Trainer for BOTOX® Cosmetic, Restylane & Juvederm.

COSMETIC & LASER
CONSULTANTS, LTD.

CLASSIFIED DEADLINES AND INFORMATION:

Contact: Robin Cryan, 360 Park Avenue, New York, NY 10010. (800) 379-8785, (212) 633-3160. FAX: (212) 633-3820.
Email ad to: r.cryan@elsevier.com

The Resources.

The Rewards.

*The Spirit of
PeaceHealth.*

At PeaceHealth in Longview, Washington, we pride ourselves on being a diverse family of individuals united by a common purpose and attributes. PeaceHealth Medical Group is a 60-member multi-specialty group and offers a well-established practice with over 25 years in the community. With a new facility and excellent staff and clinical resources, the practice has an onsite laboratory, imaging, and other physician specialists. The Family Medicine team is also adjacent to St. John Medical Center, a 180 bed, not-for-profit, JCAHO accredited facility. Our community has drawn a world-class medical staff of 175 physicians, representing 36 specialties, serving a regional population of 150,000.

Board Certified/Board Eligible Family Practice Physician

Join our 18-member Family Practice team. This practice offers full spectrum Family Medicine, with or without OB, providing evening and weekend RN triage call support, utilizing a fully integrated Electronic Medical Record system, and providing support for disease management for patients.

PeaceHealth is ideally situated on the Columbia River, where mountains and beaches are one hour away. This family-friendly, traffic-free area offers the opportunity to work in a small town community while enjoying quick access to all that Portland, OR and Seattle, WA have to offer.

Please contact Carol Shea,
Physician Recruitment,
at (360) 414-7867 or E-mail:
cshea@peacehealth.org.



PeaceHealth
Medical Group

Dedicated to Exceptional Medicine
and Compassionate Care

www.peacehealth.org

PeaceHealth is an AA/Equal Opportunity Employer.